formocortal
Small moleculeexperimental
Formocortal (INN), also known as fluoroformylone, is a corticosteroid used in dermatology and ophthalmology. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Jan 31, 2022 (NCT05018598)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFormocortal ↗
Also known as
- cutisterol
- deflamene
- fluoformylon
- fluoroformylon
- fluoroformylone
- formocortal
- formocortal
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05477108 | Phase 1 | Jul 29, 2022 | AstraZeneca, Parexel |
| NCT05018598 | Phase 4 | Jan 31, 2022 | Chiesi |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2022 |
| Chiesi | For profit | 1 | 1 | 1 | 2022 |
| Parexel | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1